Last reviewed · How we verify
amlodipine/hydrochlorothiazide
Amlodipine relaxes blood vessels by blocking calcium channels, while hydrochlorothiazide reduces blood volume by increasing sodium and water excretion through the kidneys, together lowering blood pressure.
Amlodipine relaxes blood vessels by blocking calcium channels, while hydrochlorothiazide reduces blood volume by increasing sodium and water excretion through the kidneys, together lowering blood pressure. Used for Hypertension, Angina pectoris (amlodipine component).
At a glance
| Generic name | amlodipine/hydrochlorothiazide |
|---|---|
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Calcium channel blocker / Thiazide diuretic combination |
| Target | L-type voltage-gated calcium channel (amlodipine); Sodium-chloride cotransporter (hydrochlorothiazide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing circulating blood volume. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Angina pectoris (amlodipine component)
Common side effects
- Peripheral edema
- Headache
- Dizziness
- Hypokalemia
- Hyperglycemia
- Hyperuricemia
- Flushing
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension (PHASE4)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
- INTERVENCION Trial (PHASE4)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Role of ARNi in Ventricular Remodeling in Hypertensive LVH (PHASE2)
- Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: